SGAM
ARCT icon

Smith Group Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Smith Group Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7,890
Closed -$86K – 361
2019
Q4 		$86K Hold
7,890
– – ﹤0.01% 245
2019
Q3 		$81K Buy
+7,890
New +$85.3K ﹤0.01% 249

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
DI
DFPG Investments Sandy, Utah $1.28B AUM 27.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Smith Group Asset Management's ARCT Position: Q1 2020 in Review

Smith Group Asset Management sold out of Arcturus Therapeutics (ARCT) in Q1 2020, closing a stake of 7,890 shares — an estimated $86K sold.

Smith Group Asset Management first reported a position in ARCT in Q3 2019 and held it in 2 quarters. The position peaked at $86K in Q4 2019. 53 funds tracked by Wall St. Rank hold ARCT as of Q1 2020.

  • Smith Group Asset Management reported no remaining Arcturus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Smith Group Asset Management sold 7,890 Arcturus Therapeutics shares in Q1 2020, an estimated $86K.
  • Smith Group Asset Management first reported a position in Arcturus Therapeutics in Q3 2019 and held it in 2 quarters.
  • Smith Group Asset Management's Arcturus Therapeutics position peaked at $86K in Q4 2019.
  • 53 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2020.

Based on Smith Group Asset Management's 13F filing for Q1 2020, filed 12 May 2020.